Depo-Provera Brain Tumor Lawsuits

The Progesterone Receptor Mechanism

Meningiomas express progesterone receptors (PR) at rates of 60–80%, making them highly sensitive to progestational hormones. Medroxyprogesterone acetate (MPA) — the active ingredient in Depo-Provera — is a potent synthetic progestin that binds to these receptors with high affinity. When MPA binds to progesterone receptors on meningioma cells, it can stimulate proliferation and tumor growth. This mechanism has been documented since at least 1983, when early studies first identified the progesterone-meningioma connection.

The dose-response relationship is critical to the litigation. Depo-Provera delivers 150mg of MPA per injection — a supraphysiological dose that maintains serum MPA levels far above natural progesterone levels for months. With quarterly injections over years, cumulative progestin exposure becomes enormous. The French study (Roland et al., BMJ 2024) found a 5.6x risk increase for long-term users, while the U.S. study found a dose-dependent relationship: 23% increased odds for ≤1 year use, rising to 250% increased odds for >3 years of use.

Upjohn's Troubled FDA History (1967–1992)

The regulatory history of Depo-Provera is central to the litigation. Upjohn Company first sought FDA approval in 1967, but the agency identified cancer concerns — beagle dogs receiving MPA developed breast tumors. The FDA rejected the application. Upjohn reapplied in 1978, and the FDA again rejected it after a seven-year beagle study showed two animals with malignant breast tumors out of 36 tested. A rare FDA Public Board of Inquiry in 1983 also resulted in rejection.

Despite three FDA rejections over 25 years, Depo-Provera was widely used internationally — the WHO included it in its essential medicines list. The FDA finally approved Depo-Provera in October 1992, after Upjohn submitted additional studies. Pfizer acquired Pharmacia & Upjohn in 2002, inheriting both the drug and its regulatory history.

International Regulatory Actions

The international regulatory timeline strengthens the failure-to-warn case. Canada added meningioma to the Depo-Provera label as an adverse reaction in 2015. New Zealand's Medsafe issued an alert in 2024. The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the evidence in 2024 and recommended meningioma warnings for all injectable MPA products and oral formulations containing 100mg+ of MPA. The EMA specifically recommended that MPA be contraindicated in patients with existing meningiomas.

The U.S. FDA did not act until December 2025 — and only after rejecting Pfizer's first label supplement attempt in 2024. Plaintiffs argue that Pfizer was aware of the international warnings and could have voluntarily updated the U.S. label at any time through the Changes Being Effected (CBE) regulatory pathway, which allows manufacturers to add safety information without prior FDA approval.

Bone Density Loss and the Black Box Warning

Meningioma is not the only serious Depo-Provera risk. In 2004, the FDA added a black box warning — its most serious safety communication — regarding bone mineral density loss. Long-term Depo-Provera use causes significant calcium loss from bones, increasing fracture risk. The FDA limited recommended use to 2 years unless no alternative contraceptive is adequate. Despite this warning, many women continued receiving injections beyond the 2-year recommendation.

The bone density warning is relevant to the meningioma litigation because it demonstrates a pattern: risks associated with long-term use that Pfizer and the FDA were slow to address. The intersection of bone loss and meningioma risk creates a particularly compelling narrative for women who used Depo-Provera for extended periods.

Clinical Presentation and Diagnosis

Meningiomas grow slowly and symptoms develop gradually, often over years. Common symptoms include persistent headaches that worsen over time, visual changes (blurred vision, double vision, visual field loss), seizures (occurring in over one-third of meningioma patients), hearing loss or tinnitus, weakness or numbness in extremities, cognitive changes and memory problems, and personality or behavioral changes.

Diagnosis requires neuroimaging — typically a contrast-enhanced MRI of the brain. Current clinical guidelines do NOT recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label (December 2025) instructs providers to "monitor patients on Depo-Provera CI for signs and symptoms of meningioma" and to "discontinue Depo-Provera CI if a meningioma is diagnosed." Women experiencing new or worsening headaches, visual changes, or seizures after Depo-Provera use should request brain imaging.

The June 2026 Settlement in Principle

On June 15, 2026, U.S. District Judge M. Casey Rodgers, who oversees the consolidated federal litigation in the Northern District of Florida, entered an order noting that Pfizer had reached an agreement in principle with the plaintiffs' leadership in MDL 3140. Law360 reported the development the following day. The agreement is intended to give women whose meningioma claims are already consolidated in the federal MDL an opportunity to resolve them without individual trials.

The settlement is not final. As of July 2026, the parties are still negotiating and documenting the specific terms, and no dollar figures have been made public — neither a total settlement fund nor any per-plaintiff or per-tier amounts. Any figures circulating online are estimates, not confirmed terms. A settlement in principle is an agreement to keep working toward a resolution; it does not by itself pay any claim.

Two limits matter. Pfizer has stated the agreement contains no admission of liability or wrongdoing, and the company continues to maintain that Depo-Provera is safe and effective. And the agreement covers claims in the federal MDL — Pfizer has said it does not affect cases pending in state courts, where separate dockets in Delaware, California, New York and elsewhere continue on their own tracks.

In the wake of the announcement, the court vacated upcoming bellwether trial deadlines and postponed a scheduled hearing on the parties' expert evidence while the terms are finalized. As of July 2026, more than 5,830 meningioma cases were consolidated in MDL 3140 — up from roughly 2,000 a year earlier.

Why Timing Still Matters

A settlement in principle does not remove the deadlines that govern these claims. Every state sets its own statute of limitations — the legal window to file — and for meningioma cases that clock is often measured from when a woman knew, or reasonably should have known, that her tumor may be linked to Depo-Provera. Those deadlines vary by state and by the facts of each case, and once a filing window closes it generally cannot be reopened.

How an emerging settlement treats claims filed after it is announced is one of the details still being worked out. Global resolutions of this kind are typically built around the cases already on file, which is why women who believe they qualify are generally advised to have their eligibility evaluated promptly rather than waiting for final terms. People's Justice does not file claims or provide legal advice; we investigate the reported Depo-Provera meningioma link and connect people who may qualify with attorneys who handle these cases. Outcomes vary, and no result is ever guaranteed.